ONC201 for the Treatment of Vascular Aneurysms
Application
A repurposed therapeutic for the preventative and treatment of aneurysms.
Key Benefits
A repurposed cancer drug that targets cells known to be damaged during the progression of an aneurysm.
The drug has been tested within an animal model of aortic aneurysms, where it prevented the severe complications of the disease and protected the...
Published: 5/23/2023
Contributor(s): Alejandra Maria San Martin
|
Therapeutic to Treat Age-Dependent Idiopathic Pulmonary Fibrosis
Application
Therapeutic for treating age-associated lung fibrosis.
Key Benefits
Tecfidera (dimethyl fumarate - DMF) is an FDA approved therapy to treat multiple sclerosis via oral administration.
A novel formulation for inhaled delivery demonstrated efficacy for a new indication: Idiopathic Pulmonary Fibrosis (IPF), where it promotes the reversal...
Published: 5/8/2023
Contributor(s): Louise Hecker, Kosuke Kato, Priyadarshini Muralidharan, Heidi Mansour
|
Use of MAST1 Inhibitor in Treatment of Platinum-Based Chemotherapy
Application
A combination therapy product for treatment of patients having cisplatin-resistant cancer.
Key Benefits
Identified the use of MAST1 inhibitors (such as lestaurtinib) to target cisplatin-resistant cancer.
Lestaurtinib sensitized cells to cisplatin treatment the most using a concentration that attenuates cell viability by less...
Published: 5/23/2023
Contributor(s): Sumin Kang, Jing Chen, Lingtao Jin
|
IACS-0107059 for Sensitizing Resistant Multiple Myeloma (MM) for Venetoclax Therapy
Application
Combinatorial drug therapy for resistant multiple myeloma.
Key Benefits
Clinically approved drugs to repurpose for multiple myeloma.
Therapies for multiple myeloma that is resistant to other therapies.
Market Summary
Multiple myeloma (MM) is a plasma cell malignancy. Despite the use of next generation immunomodulatory drugs...
Published: 5/4/2023
Contributor(s): Malathy (mala) Shanmugam, Aditi Sharma
|
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application
A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients.
Key Benefits
Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients.
A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients.
Market...
Published: 5/8/2023
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
Repurposed Treatment for Cocaine Use Disorder
Application
Repurposed drug for transcriptomic-driven treatment of cocaine use disorder.
Key Benefits
FDA-approved drug.
Outperformed current targets undergoing clinical trials for CUD at the mRNA level.
Market Summary
Cocaine abuse is associated with substantial morbidity and mortality, and there are no approved medications for the treatment...
Published: 5/23/2023
Contributor(s): Rohan Palmer, Spencer Huggett
|
Drug Combination to Treat Lung Cancer Metastasis
Application
Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis.
Key Benefits
Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792).
Has potential to prevent metastasis in a variety of cancers.
Decreases both cell viability and invasive area.
Repurposed drugs.
Market Summary
Metastatic...
Published: 4/5/2023
Contributor(s): Malathy (mala) Shanmugam, Adam Marcus
|
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application
Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages.
Key Benefits
Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi.
Relatively low regulatory risk because many...
Published: 4/5/2023
Contributor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
|
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application
Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries.
Key Benefits
Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries.
Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 8/5/2022
Contributor(s): Ahsan Husain, Nawazish Naqvi
|
Combination Therapy to Treat Pediatric Brain Tumor
Application
Combination therapy (inhibition of STAT3 and YB-1) to treat medulloblastoma.
Key Benefits
Drug combination targets cancer stem cells.
Increased apoptosis of cancer cells compared to current chemotherapeutic agents.
Market Summary
Medulloblastoma (MB) is the most common cancerous brain tumor that affects children and survival rates...
Published: 5/4/2023
Contributor(s): Tobey John MacDonald, Anna Kenney, James Felker, Abhinav Dey
|